Heyuan Bio Announces China's First Indigenous CD19 CAR-T Therapy, YORWIDA (Inaticabtagene Autoleucel Injection), Receives NMPA Approval for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

36Kr learned that, according to the official WeChat account of Juventas, the National Medical Products Administration (NMPA) has officially approved the New Drug Application (NDA) for the company's immunotherapy CAR-T product Yuan Ruida® (Inaticabtagene Autoleucel Injection, CNCT19 Cell Injection) for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). It is reported that Inaticabtagene Autoleucel Injection is the first CD19 CAR-T cell therapy product with full independent intellectual property rights in China and also the first CAR-T cell therapy product in the field of leukemia treatment in China.Original Link